Sign in to fuzzto save your conversations, follow your research and come back anytime.
Kwality Pharmaceuticals
SectorHealthcare
In the news
Kwality Pharma hits 52-week high of ₹3,725.45 on strong Q4 results
CDMO Showdown: Gland, Akums, and Kwality—Three Paths to Growth
Kwality Pharma raises FY27 guidance, Q1 profit up 3.2% to ₹25.7 crore
Kwality Pharmaceuticals hits 52-week high on strong Q4 results
Kwality Pharmaceuticals Q4 profit surges 74.60% to ₹25.30 crore
Company insights, generated from the most recent coverage.
Highest long-term risk (4+ years) due to developmental stage of biologics pipeline, reliance on clinical trial success, and 90% revenue dependence on out-licensing partnerships.
CDMO business limited to pharmaceutical formulations with no non-pharmaceutical or consumer healthcare capabilities, restricting addressable market expansion compared to diversified peers like Akums.
Filing engine grew 166% from 75 in FY23 to 200 in FY26, enabling rapid global regulatory coverage — single dossier from regulated markets can be leveraged across 60-70 countries.